CVRx, Inc. announced the enrollment of the first patient in the BENEFIT-HF trial, a major study testing Barostim therapy in a larger heart failure patient group. The trial will enroll 2,500 patients across 150 centers in the US and Germany, aiming to evaluate mortality and heart failure events. If successful, it could triple the eligible patient population for Barostim, broadening access to this FDA-approved neuromodulation device. The trial is expected to run through 2032, potentially strengthening Barostim's role in heart failure treatment.
Adobe's Chief People Officer, Gloria Chen, sold 1,607 shares of Adobe stock to cover tax withholding related to her compensation. This transaction is a routine financial move tied to employee stock benefits and does not indicate any change in company...
Bank of Marin Bancorp reported a strong second quarter with earnings per share of $0.58, beating analyst estimates by over 11% and more than doubling last year's EPS of $0.29. The bank's revenue rose 16.8% year-over-year to $34.1 million, surpassing ...
LVMH is set to report Q3 earnings with an expected EPS of $2.47 and revenue of $22.02 billion, following strong Q2 sales of $22.20 billion driven by U.S. demand. The luxury goods company, which owns brands like Louis Vuitton and Dior, shows a P/E rat...
Sierra Bancorp reported Q2 earnings per share (EPS) of $0.77, below analyst expectations of $0.89, and revenue of $38.98 million, missing the forecast of $39.59 million. The EPS slightly declined from $0.78 a year ago, indicating a small year-over-ye...
Navitas Semiconductor, a maker of AI data center power chips, has seen its stock fall 40% this month, making its upcoming earnings report crucial. Analysts expect a loss of $0.04 per share and revenue near $10 million, reflecting a 31.3% decline from...
